Implications for risk assessment of suggested nongenotoxic mechanisms of chemical carcinogenesis

Environmental Health Perspectives

Volumn 104, Issue SUPPL. 1, 1996, Pages 123-134

  Melnick, Ronald L ^a   Kohn, Michael C ^a   Portier, Christopher J ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

Mitogenesis; Nongenotoxic carcinogenic mechanisms; Peroxisome proliferators; Receptor mediated carcinogenesis; Regenerative hyperplasia; 2 microglobulin nephropathy

Indexed keywords

ALPHA 2 MACROGLOBULIN; CYTOTOXIC AGENT; DIOXIN; PEROXISOME PROLIFERATOR; TRIHALOMETHANE;

CANCER RISK; CARCINOGENESIS; CELL DIVISION; CHEMICAL CARCINOGENESIS; CLASSIFICATION; CYTOTOXICITY; DNA DAMAGE; DOSE RESPONSE; HUMAN; KIDNEY DISEASE; MITOGENESIS; NONHUMAN; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW; RISK ASSESSMENT; TUMOR PROMOTION;

ANIMALIA;

EID: 0029882013     PISSN: 00916765     EISSN: None     Source Type: Journal    
DOI: 10.1289/ehp.96104s1123     Document Type: Review

References (122)

1. Parera FP. Perspectives on the risk assessment for non-genotoxic carcinogens and tumor promoters. Environ Health Perspect 94:231-235 (1991).
2. Schulte-Hermann R, Timmermann-Trosiener I, Schuppler J. Promotion of spontaneous preneoplastic cells in rat liver as a possible explanation of tumor production by nonmutagenic compounds. Cancer Res 43:839-844 (1983).
3. Neumann I, Thierau D, Andrae U, Greim H, Schwarz LR. Cyproterone acetate induces DNA damage in cultured rat hepatocytes and preferentially stimulates DNA synthesis in glutamyltranspeptidse-positive cells. Carcinogenesis 13:373-378 (1992).
4. Topinka J, Andrae U, Schwarz LR, Wolff T. Cyproterone acetate generates DNA adducts in rat liver and in primary rat hepatocyte cultures. Carcinogenesis 14:423-427 (1993).
5. Demi E, Schwarz LR, Oesterle D. Initiation of enzyme-altered foci by the synthetic steroid cyproterone acetate in rat liver foci bioassay. Carcinogenesis 14:1229-1231 (1993).
6. Williams GM, Iatropoulos MJ, Djordjevic MV, Kaltenverg OP. The triphenylethylene drug tamoxifen is a strong liver carcinogen in the rat. Carcinogenesis 14:315-317 (1993).
7. Greaves P, Goonetilleke R, Nunn G, Topham J, Orton T. Two-year carcinogenicity study of tamoxifen in Alderley Park Wistar-derived rats. Cancer Res 53:3919-3924 (1993).
8. Tucker MJ, Adam HK, Patterson JS. Tamoxifen. In: Safety Testing of New Drugs. Laboratory Predictions and Clinical Performance (Laurence DR, McLean AEM, Wetherall M, eds). London Academic Press', 1984;125-161.
9. Han XL, Liehr JG. Induction of covalent DNA adducts in rodents by tamoxifen. Cancer Res 52:1360-1363 (1992).
10. 32P-postlabeling and use of metabolic inhibitors for two distinct pathways leading to mouse hepatic DNA adduct formation and identification of 4-hydroxytamoxifen as a proximate metabolite. Carcinogenesis 15:2087-2094 (1994).
11. Pathak DN, Bodell WJ. DNA adduct formation by tamoxifen with rat and human liver microsomal activation systems. Carcinogenesis 15:529-532 (1994).
12. Styles JA, Davies A, Lim CK, De Matteis F, Stanley LA, White INH, Yuan ZX, Smith LI. Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450s. Carcinogenesis 15:5-9 (1994).
13. Vancutsem PM, Lazarus P, Williams GM. Frequent and specific mutations of the rat p53 gene in hepatocarcinomas induced by tamoxifen. Cancer Res 54:3864-3867 (1994).
14. Stott WT, Reitz RH, Schumann AM, Watanabe PG. Genetic and nongenetic events in neoplasia, Food Cosmet Toxicol 19:567-576 (1981).
15. Ames BN, Gold LS. Too many rodent carcinogens: mitogenesis increases mutagenesis. Science 249:970-971 (1990).
16. Cohen SM, Ellwein LB. Cell proliferation in carcinogenesis. Science 249:1007-1011 (1990).
17. Farber E. Sequential events in chemical carcinogenesis. In: Cancer: A Comprehensive Treatise (Becker FF, ed) Vol 1, 2d ed. New York: Plenum, 1982;485-506.
18. Weinstein, IB. Mitogenesis is only one factor in carcino- genesis. Science 251:387-388 (1991).
19. Tomatis L. Cell proliferation and carcinogenesis: a brief historical background and current view based on an IARC workshop report. Environ Health Perspect 101 (Suppl 5):149-152 (1993).
20. Melnick RL, Huff J, Barrett JC, Maronpot RR, Lucier G, Portier CJ. Cell proliferation and chemical carcinogenesis: symposium overview. Environ Health Perspect 101 (Suppl 5):3-8 (1993).
21. Melnick RL Huff JE. Liver carcinogenesis is not a predicted outcome of chemically induced hepatocyte proliferation. Toxicol Ind Health 9:415-438 (1993).
22. Peraino C, Fry RJM, Staffeldt E, Christopher JP. Enhancing effects of phenobarbitone and butylated hydroxytoluene on 2-acetylaminofluorene-induced hepatic tumorigenesis in the rat. Food Cosmet Toxicol 15:93-96 (1977).
23. Peraino C, Fry RJM, Staffeldt E, Kisieleski WE. Effects of varying the exposure to phenobarbital on its enhancement of 2-acetylaminofluorene-induced hepatic tumorigenesis in the rat. Cancer Res 33:2701-2705 (1973).
24. Bucher JR, Huff JE, Jokinen MP, Haseman JK, Stedham M, and Cholakis JM. Inhalation of tetranitromethane causes nasal passage irritation and pulmonary carcinogenesis in rodents. Cancer Lett 57:95-101 (1991).
25. Larson JL, Wolf DC, Butterworth BE. Induced cytotoxicity and cell proliferation in the hepatocarcinogenicity of chloroform in female B6C3F1 mice: comparison of administration by gavage in corn oil vs ad libitum in drinking water. Fundam Appl Toxicol 22:90-102 (1994).
26. Jorgenson TA, Meierhenry EF, Rushbrook CJ, Bull RJ, Robinson M. Carcinogenicity of chloroform in drinking water to male Osborne-Mendel rats and female B6C3F1 mice. Fundam Appl Toxicol 5:760-769 (1985).
27. Corley RA, Mendrala AL, Smith FA, Staats DA, Gargas ML, Conolly RB, Andersen ME, Reitz RH. Development of a physiologically based pharmacokinetic model for chloroform. Toxicol Appl Phamacol 103:512-527 (1990).
28. Larson JL, Wolf DC, Morgan KT, Mery S, Butterworth BE. The toxicity of 1-week exposures to inhaled chloroform in female B6C3F1 mice and male F-344 rats. Fundam Appl Toxicol 22:431-446 (1994).
29. Rosenthal SL. A review of the mutagenicity of chloroform. Environ Mol Mutagen 10:211-226 (1987).
30. Morimoto K and Koizumi A. Trihalomethanes induce sister chromatid exchanges in human lymphocytes in vitro and mouse bone marrow cells in vivo. Environ Res 32:72-79 (1983).
31. Callen DF, Wolf CR, Philpot RM. Cytochrome P-450 mediated genetic activity and cytotoxicity of seven halogenated aliphatic hydrocarbons in Saccharomyces cerevisiae. Mutat Res 77:55-63 (1980).
32. DiRenzo AB, Gandolfi AJ, Sipes IG. Microsomal bioactivation and covalent binding of aliphatic halides to DNA. Toxicol Lett 11:243-252 (1982).
33. Ahmed AE, Kubic VL, and Anders MW. Metabolism of haloforms to carbon monoxide. I. In vitro studies. Drug Metab Dispos 5:198-204 (1977).
34. Docks EL, Krishna G. The role of glutathione in chloroform-induced hepatotoxicicy. Exp Mol Pathol 24:13-22 (1976).
35. Pohl LR, Martin JL, Taburet AM, George JW. Oxidative bioactivation of haloforms into hepatotoxins. In: Microsomes, Drug Oxidations, and Chemical Carcinogenesis, Vol II (Coon MJ, Conney AH, Estabrook RW, Gelboin HV, Gillette JR, O'Brein PJ, eds), Academic Press, New York;881-884 (1980).
36. Pitzer KS. Quantum Chemistry. Englewood Cliffs, NJ:Prentice-Hall, 1953;170.
37. Dunnick JK, Melnick RL. Assessment of the carcinogenic potential of chlorinated water: experimental studies of chlorine, chloramine, and trihalomethanes. J Natl Cancer Inst 85:817-822 (1993).
38. Thornton-Manning JR, Seely JC, Pegram RA. Toxicity of bromodichloromethane in female rats and mice after repeated oral dosing. Toxicology 94:3-18 (1994).
39. Roy AK, Neuhaus OW. Androgenic control of a sex-dependent protein in the rat. Nature 214:618-620 (1967).
40. 2μ-globulin in the renal proximal tubules of male rats exposed to unleaded gasoline. Toxicol Appl Pharmacol 90:43-51 (1987).
41. 2μ-globulin and albumin by adult male rats following treatment with nephrotoxic agents. Nephron 28:133-140 (1981).
42. 2μ-globulin nephropathy. Toxicol Appl Pharmacol 97:35-46 (1989).
43. 2μ-globulin-xenobiotic conjugates. Toxicol Appl Pharmacol 103:539-548 (1990).
44. Short BG, Burnett VL, Cox MG, Bus JS, Swenberg JA. Site-specific renal cytotoxicity and cell proliferation in male rats exposed to petroleum hydrocarbons. Lab Invest 57:564-577 (1987).
45. 2μ-globulin in F344 rats during chronic exposure to unleaded gasoline or 2,2,4-trimethylpentane. Toxicol Appl Pharmacol 101:414-431 (1989).
46. 2μ-globulin is necessary for d-limonene promotion of male rat kidney tumors. Cancer Res 51:3512-3521 (1991).
47. Short BG, Steinhagen WH, Swenberg JA. Promoting effects of unleaded gasoline and 2,2,4-trimethylpentane on the development of atypical cell foci and renal tubular cell tumors in rats exposed to N-ethyl-N-hydroxyethylnitrosamine. Cancer Res 49:6369-6378 (1989).
48. Halder CA, Holdsworth CE, Cockrell BY, Piccirillo VJ. Hydrocarbon nephropathy in male rats: identification of the nephrotoxic components of unleaded gasoline. Toxicol IndHealth 1:67-87 (1985).
49. 2μ) nephropathy. Fundam Appl Toxicol 16:749-762 (1991).
50. 2μ-globulin in vitro-evaluating structure-activity relationships. Toxicol Appl Pharmacol 107:228-238 (1991).
51. 2μ-Globulin nephropathy without nephrocarcinogenesis in male Wistar rats administered 1-(aminomethyl)cyclohexaneaceitc acid. Toxicol Appl Pharmacol 111:375-387 (1991).
52. 2μ-globulin in male but not female Fischer 344 rats or male NBR rats. Toxicol Lett 53:179-181 (1990).
53. National Cancer Institute. Bioassay of lindane for possible carcinogenicity (CAS No. 58-89-9). NCI Carcinogenesis Technical Rpt No 14. Bethesda, MD:National Institutes of Health, 1977.
54. Charbonneau M, Lock EA, Strasser J, Cox MG, Turner MJ, Bus JS. 2,2,4-Trimethylpentane-induced nephrotoxicity. I. Metabolic disposition of TMP in male and female Fischer 344 rats. Toxicol Appl Pharmacol 91:171-181 (1987).
55. 2μ-globulin. Toxicol Appl Pharmacol 91:182-192 (1987).
56. 2μ-globulin. Toxicol Appl Pharmacol 99:250-259 (1989).
57. 2μ-globulin) nephropathy in renal carcinogenesis. Regul Toxicol Pharmacol 16:111-125 (1992).
58. Charbonneau M, Lock EA, Strasser J, Short BG, Bus JS. Nephrotoxicity of 2,2,4-trimethylpentane (TMP) metabolites in male Fischer 344 rats. Toxicologist 7:89 (1987).
59. Solleveld HA, Haseman JK, McConnell EE. Natural history of body weight gain, survival, and neoplasia in the F344 rat. J Natl Cancer Inst 72:929-940 (1984).
60. 2μ-globulin nephropathy and renal cell proliferation. Toxicol Lett 63:21-33 (1992).
61. Barrett JC, Huff JE. Cellular and molecular mechanisms of chemically induced renal carcinogenesis. Renal Failure 13:211-225 (1991).
62. Pevsner J, Reed RR, Feinstein PG, Snyder SH. Molecular cloning of odorant-binding protein: member of a ligand carrier family. Science 241:336-339 (1988).
63. 2μ-Globulin is the only member of the lipocalin protein superfamily that binds to hyaline droplet inducing agents. Toxicol Appl Pharmacol 116:170-176 (1992).
64. Reddy JK, Azarnoff DL, Hignite CE. Hypolipidaemic hepatic peroxisome proliferators form a novel class of chemical carcinogens. Nature 283:397-398 (1980).
65. Ashby J, Brady CR, Elcombe CR, Elliott BM, Ishmael J, Odum J, Tugwood JD, Kettle S, Purchase IFH. Mechanistically-based human hazard assessment of peroxisome proliferator-induced hepatocarcinogenesis. Human Exptl Toxicol 13:S1-S117 (1994).
66. Reddy JK, Reddy MK, Usman, MI, Lalwani ND, Rao MS. Comparison of hepatic peroxisome proliferative effect and its implication for hepatocarcinogenicity of phthalate esters, di(2-ethylhexyl) phthalate, and di(2-ethylhexyl) adipate with a hypolipidemic drug. Environ Health Perspect 65:317-327 (1986).
67. National Toxicology Program. Carcinogenesis bioassay of di(2-ethylhexyl)phthalate (CAS No. 117-81-7) in F344 rats and B6C3F1 mice (feed study). NTP Technical Rpt 217. Bethesda, MD:National Institutes of Health, 1982.
68. National Toxicology Program. Carcinogenesis bioassay of di(2-ethylhexyl)adipate (CAS No. 103-23-1). NTP Technical Rpt 212. Bethesda, MD:National Institutes of Health, 1981.
69. Marsman DS, Cattley RC, Conway JG, Popp JA. Relationship of hepatic peroxisome proliferation and replicative DNA synthesis to the hepatocarcinogenicity of the peroxisome proliferators di(2-ethylhexyl)phthalate and [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio]-acetic acid (Wy-14643) in rats. Carcinogenesis 48:6739-6744 (1988).
70. IARC. Tetrachloroethylene. In: IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Dry-Cleaning, Some Solvents and Other Industrial Chemicals, Vol 63. Lyon:International Agency for Research on Cancer, in press.
71. Hwang JJ, Hsia MTS, Jirtle RL. Induction of sister chromatid exchange and micronuclei in primary cultures of rat and human hepatocytes by the peroxisome proliferates, Wy-14,643. Mutat Res 286:123-133 (1993).
72. Tsutsui T, Watanabe E, Barrett JC. Ability of peroxisome proliferators to induce cell transformation, chromosome aberrations and peroxisome proliferation in cultured Syrian hamster embryo cells. Carcinogenesis 14:611-618 (1993).
73. Reisenbichler H, Eckl PM. Genotoxic effects of selected peroxisome proliferators. Mutat Res 286:135-144 (1993).
74. Hegi ME, Fox TR, Belinsky SA, Devereux TR, Anderson MW. Analysis of activated protooncogenes in B6C3F1 mouse liver tumors induced by ciprofibrate, a potent peroxisome proliferator. Carcinogenesis 14:145-149 (1993).
75. Reddy JK, Lalwani ND. Carcinogenesis by hepatic peroxisome proliferators: evaluation of the risk of hypolipidemic drugs and industrial plasticizers to humans. CRC Crit Rev Toxicol 12:1-58 (1983).
76. Rao MS, Lalwani ND, Watanabe TK, Reddy JK. Inhibitory effect of antioxidants ethoxyquin and 2(3)-tert-butyl-4-hydroxyanisole on hepatic tumorigenesis in rats fed ciprofibrate, a peroxisome proliferator. Cancer Res 44:1072-1076 (1984).
77. Tomaszewski KE, Agarwal DK, Melnick RL. In vitro steady-state levels of hydrogen peroxide after exposure of male F344 rats and female B6C3F1 mice to hepatic peroxisome proliferators. Carcinogenesis 7:1871-1876 (1986).
78. Reddy JK, Lalwani ND, Reddy MK, Qureshi SA. Excessive accumulation of autofluorescent lipofuscin in the liver during hepatocarcinogenesis by methyl clofenapate and other hypolipidemic peroxisome proliferators. Cancer Res 42:259-266 (1982).
79. Conway JG, Tomaszewski KE, Olson MJ, Cattley RC, Marsman DS, Popp JA. Relationship of oxidative damage to the hepatocarcinogenicity of the peroxisome proliferators di(2-ethylhexyl)phthalate and Wy-14,643. Carcinogenesis 10:513-519 (1989).
80. Takagi A, Sai K, Umemura T, Hasegawa R, Kurokawa Y. Relationship between hepatic peroxisome proliferation and 8-hydroxydeoxyguanosine formation in liver DNA of rats following long-term exposure to three peroxisome proliferators; di(2-ethylhexyl) phthalate, aluminum clofibrate and simifibrate. Cancer Lett 53:33-38 (1990).
81. Cattley RC, Glover SE. Elevated 8-hydroxydeoxyguanosine in hepatic DNA of rats following exposure to peroxisome proliferators: relationhsip to carcinogenesis and nuclear localization. Carcinogenesis 14:2495-2499 (1993).
82. Butterworth BE. Consideration of both genotoxic and nongenotoxic mechanisms in predicting carcinogenic potential. Mutat Res 239:117-132 (1990).
83. Melnick RL. Does chemically induced hepatocyte proliferation predict liver carcinogenesis? FASEB J 6:2698-2706 (1992).
84. Eacho PI, Lanier TL, Brodhecker CA. Hepatocellular DNA synthesis in rats given peroxisome proliferating agents: comparison of WY-14,643 to clofibric acid, nafenopin and LY17I883. Carcinogenesis 13:409-415 (1992).
85. Yeldandi AV, Milano M, Subbarao V, Reddy JK, Rao MS. Evaluation of liver cell proliferation during ciprofibrate-induced hepatocarcinogenesis. Cancer Lett 47:21-27, (1989).
86. Smith-Oliver T, Butterworth BE. Correlation of the carcinogenic potential of di(2-ethylhexyl)phthalate (DEHP) with induced hyperplasia rather than with genotoxic activity. Mutat Res 188:21-28 (1987).
87. Cattley RC, Marsman DS, Popp JA. Failure of the peroxisome proliferator WY-14,643 to initiate growth-selectable foci in rat liver. Toxicology 56:1-7 (1989).
88. Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347:645-650 (1990).
89. Kliewer SA, Umesono K, Noonan DJ, Heyman RA, Evans RA. Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature 358:771-774 (1992).
90. Issemann I, Prince RA, Tugwood JD, Green S. The retinoid X receptor enhances the function of the peroxisome proliferator activated receptor. Biochimie 75:251-256 (1993).
91. Sher T, Yi HF, McBride OW, Gonzalez FJ. cDNA cloning, chromosomal mapping, and functional characterisation of human peroxisome proliferator activated receptor. Biochemistry 32:5598-5604 (1993).
92. Steineger HH, Sorensen HN, Tugwood JD, Skrede S, Spyevold O, Gautvik, KM. Dexamethasone and insulin demonstrate marked and opposite regulation of the steady-state mRNA level of the peroxisomal proliferator-activated receptor (PPAR) in hepatic cells. Hormonal modulation of fatty acid-induced transcription. Eur J Biochem 225:967-974 (1994).
93. Huff JE, Salmon AG, Hooper NK, Zeise L. Long-term carcinogenesis studies on 2,3,7,8-tetrachlorodibenzo-p-dioxin and hexachlorodibenzo-p-dioxins. Cell Biol Toxicol 7:67-94 (1991).
94. Poland A, Knutson JC. 2,3,7,8-Tetrachlorodibenzo-p-dioxin and related halogenated aromatic hydrocarbons: examination of the mechanism of toxicity. Annu Rev Pharmacol Toxicol 22:517-554 (1982).
95. Whitlock JP. Mechanistic aspects of dioxin action. Chem Res Toxicol 6:754-763 (1993).
96. Roberts L. Dioxin risks revisited. Science 251: 624-626 (1991).
97. Johnson E. A partnership between the dioxin receptor and a basic helix-loop-helix protein. Science 252:924-925 (1991).
98. Kohn MC, Lucier GW, Clark GC, Sewall C, Tritscher AM, Portier CJ. A mechanistic model of effects of dioxin on gene expression in the rat liver. Toxicol Appl Pharmacol 120:138-154 (1993).
99. Andersen ME, Mills JJ, Gargas ML, Kedderis L, Birnbaum LS, Neubert D, Greenlee WF. Modeling receptor-mediated processes with dioxin: implications for pharmacokinetics and risk assessment. Risk Anal 13: 25-36 (1993).
100. Tritscher AM, Goldstein JA, Portier CJ, McCoy Z, Clark GC, Lucier GW. Dose-response relationships for chronic exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin in a rat tumor promotion model: quantification and immunolocalization of CYP1A1 and CYP1A2 in the liver. Cancer Res 52:3436-3442 (1992).
101. Vanden Heuvel JP, Clark GC, Kohn MC, Tritscher AM, Greenlee WF, Lucier GW, Bell DA. Dioxin-responsive genes: examination of dose-response relationships using quantitative reverse transcriptase-polymerase chain reaction. Cancer Res 54: 62-68 (1994).
102. Kohn MC, Lucier GW, Portier CJ. The importance of biological realism in dioxin risk assessment models. Risk Anal 14:993-1000 (1994).
103. Sloop TC, Lucier GW. Dose-dependent elevation of Ah receptor binding by TCDD in rat liver. Toxicol Appl Pharmacol 88:329-337 (1987).
104. Lin FH, Clark G, Birnbaum LS, Lucier GW, Goldstein JA. Influence of the Ah locus on the effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin on the hepatic epidermal growth factor receptor. Mol Pharmacol 39: 307-313 (1991).
105. Schlessinger J, Schreiber AB, Levi A, Lax I, Liberman T, Yarden Y. Regulation of cell proliferation by epidermal growth factor. CRC Crit Rev Biochem 14:93-111 (1983).
106. Mead JE, and Fausto N. Transforming growth factor-α may be a physiological regulator of liver regeneration by means of an autocrine mechanism. Proc Natl Acad Sci USA 86:1558-1562 (1989).
107. Choi EJ, Toscano DG, Ryan JA, Riedel N, Toscano WA. Dioxin induces transforming growth factor-α in human keratinocytes. J Biol Chem 266:9591-9597 (1991).
108. Sewall C, Lucier G, Tritscher A, Clark G. TCDD-mediated changes in hepatic EGF receptor may be a critical event in the hepatocarcinogenic action of TCDD. Carcinogenesis 14:1885-1893 (1993).
109. Li SA, Klicka JK, Li JJ. Estrogen 2- and 4-hydroxylase activity, catechol estrogen formation, and implications for estrogen carcinogenesis in the hamster kidney. Cancer Res 45:181-185 (1985).
110. Bagchi M, and Stohs S.J. In vitro induction of reactive oxygen species by 2,3,7,8-tetrachlorodibenzo-p-dioxin, endrin, and lindane in rat peritoneal macrophages and heparic mitochondria and microsomes. Free Radic Biol Med 14:11-18 (1993).
111. Tsibris JCM, and McGuire P. Microsomal activation of estrogens and binding to rat liver DNA in vivo by selective induction of microsomal and nuclear aryl hydrocarbon hydroxylase activity. Cancer Res 38:4640-4644 (1977).
112. Cerutti P. Repairable damage in DNA. In: DNA Repair Mechanisms (Hanawalt P, Friedberg E, Fox C, eds). New York:Academic Press,1978;1-14.
113. Portier CJ, Kohn M, Sherman CD, and Lucier G. Modeling the number and size of hepatic focal lesions following exposure to 2,3,7,8-TCDD, Organohalogen Compounds 21:393-397 (1994).
114. Bock KW. Roles of UDP-glucuronosyltransferases in chemical-carcinogenesis. Crit Rev Biochem Mol Biol 26:129-150 (1991).
115. Sewall CH, Flagler N, Vanden Heuvel JP, Lucier GW. Alterations in thyroid function in female Sprague-Dawley rats following chronic treatment with 2,3,7,8-tetrachlorodibenzo-p-dioxin. Toxicol Appl Pharmacol 132:237-244 (1995).
116. Saito K, Kaneko H, Sato K, Yoshitake A, Yamada H. Hepatic UDP-glucuronyltransferase(s) activity toward thyroid hormones in rats: induction and effects on serum thyroid hormone levels following treatment with various enzyme inducers. Toxicol Appl Pharmacol 111:99-106 (1991).
117. Barter RA, Klaassen CD. UDP-glucuronosyltransferase inducers reduce thyroid hormone levels in rats by an extrathyroidal mechanism. Toxicol Appl Pharmacol 113:36-42 (1992).
118. Andrae U, Greim H. Initiation and promotion in thyroid carcinogenesis. In: Tissue Specific Toxicity: Biochemical Mechanisms. New York:Academic Press, 1992;71-93.
119. Kohn MC. Computer simulation of effects of dioxin on thyroid hormones in the rat. In: Health Sciences, Physiological and Pharmacological Simulation Studies (Anderson JG, Katzper M, eds). La Jolla, CA:Society for Computer Simulation, 1995;117-122.
120. Kohn MC, Sewall CH, Lucier, GW, Portier CJ. A mechanistic model of effects of dioxin on thyroid hormones in the rat. Toxicol Appl Pharmacol (in press).
121. Portier C, Tritscher A, Kohn M, Sewall C, Clark G, Edler L, Hoel D, Lucier G. Ligand/receptor binding for 2,3,7,8-TCDD: Implications for risk assessment. Fundam Appl Toxicol 20:48-56 (1992).
122. Kohn MC, Portier CJ. Effects of the mechanism of receptor-mediated gene expression on the shape of the dose-response curve. Risk Anal 13:565-572 (1993).